多中心回顾性队列研究定义COVID-19肾脏病理谱
该国际多中心回顾性队列研究评估了284例COVID-19患者的肾活检病理,并与疫情前63,575例原生肾活检及13,955例移植肾活检对比。研究发现原生肾活检最常见诊断为塌陷性肾小球病(25.8%),且91.7%病例携带高危APOL1基因型;移植肾活检主要诊断为排斥反应(61.4%)。未发现SARS-CoV-2直接感染肾脏的证据。
要点
- COVID-19患者原生肾活检最常见为塌陷性肾小球病,与高危APOL1基因型高度相关。
- 移植肾活检中急性肾损伤主要病因为排斥反应,未发现直接病毒感染。
- 相比疫情前,肌红蛋白管型肾病和单克隆IgG增殖性肾小球肾炎频率增加。
核心结论
- COVID-19患者肾脏疾病谱以塌陷性肾小球病为主,且高频携带高危APOL1基因型。
- 未发现SARS-CoV-2直接感染肾脏的证据。
研究设计与样本
- 国际多中心回顾性队列研究,评估284例COVID-19患者肾活检。
- 对照疫情前63,575例原生肾活检和13,955例移植肾活检。
- 对107例非裔美国人和西班牙裔患者进行APOL1 G1/G2基因分型。
- 对273例进行SARS-CoV-2免疫组化检测。
主要发现
- 原生肾活检主要指征为急性肾损伤(45.4%),其次为蛋白尿伴或不伴急性肾损伤(42.6%)。
- 非裔美国患者占44.6%,多于其他族裔。
- 原生肾活检最常见诊断为塌陷性肾小球病(25.8%),其中91.7%病例携带高危APOL1基因型。
- 相比五年活检数据库,肌红蛋白管型肾病和伴单克隆IgG沉积的增殖性肾小球肾炎频率增加(分别为3.3%和1.7%)。
- 移植肾活检主要指征为急性肾损伤(86.4%),主要诊断为排斥反应(61.4%)。
关键数值与推荐
- 原生肾活检中塌陷性肾小球病占25.8%,高危APOL1基因型占该病的91.7%。
- 移植肾活检中急性肾损伤占86.4%,排斥反应占61.4%。
临床怎么用
- 对COVID-19合并急性肾损伤患者,尤其非裔美国人,应警惕塌陷性肾小球病并考虑APOL1基因检测。
- 移植肾受者出现急性肾损伤时,需优先排查排斥反应。
- 肾脏病理中未发现直接病毒感染的证据,提示肾损伤机制可能间接。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Kidney failure is common in patients with Coronavirus Disease-19 (COVID-19), resulting in increased morbidity and mortality. In an international collaboration, 284 kidney biopsies were evaluated to improve understanding of kidney disease in COVID-19. Diagnoses were compared to five years of 63,575 native biopsies prior to the pandemic and 13,955 allograft biopsies to identify diseases that have increased in patients with COVID-19. Genotyping for APOL1 G1 and G2 alleles was performed in 107 African American and Hispanic patients. Immunohistochemistry for SARS-CoV-2 was utilized to assess direct viral infection in 273 cases along with clinical information at the time of biopsy. The leading indication for native biopsy was acute kidney injury (45.4%), followed by proteinuria with or without concurrent acute kidney injury (42.6%). There were more African American patients (44.6%) than patients of other ethnicities. The most common diagnosis in native biopsies was collapsing glomerulopathy (25.8%), which was associated with high-risk APOL1 genotypes in 91.7% of cases. Compared to the five-year biopsy database, the frequency of myoglobin cast nephropathy and proliferative glomerulonephritis with monoclonal IgG deposits was also increased in patients with COVID-19 (3.3% and 1.7%, respectively), while there was a reduced frequency of chronic conditions (including diabetes mellitus, IgA nephropathy, and arterionephrosclerosis) as the primary diagnosis. In transplants, the leading indication was acute kidney injury (86.4%), for which rejection was the predominant diagnosis (61.4%). Direct SARS-CoV-2 viral infection was not identified. Thus, our multi-center large case series identified kidney diseases that disproportionately affect patients with COVID-19 and demonstrated a high frequency of APOL1 high-risk genotypes within this group, with no evidence of direct viral infection within the kidney.
引用
- May RM, Cassol C, Hannoudi A, et al. A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney Int. 2021. PMID: 34352311. doi:10.1016/j.kint.2021.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。